Methimazole embryofetopathy is a rare birth defect that is caused by a pregnant woman taking the drug methimazole during the first trimester of pregnancy. The drug is used to treat hyperthyroidism, but it can cause serious birth defects if taken during the first trimester. These birth defects can include heart defects, cleft lip and palate, and other physical and mental disabilities.

The symptoms of Methimazole embryofetopathy vary depending on the severity of the condition, but may include:

- Low birth weight
- Abnormal facial features
- Cleft lip or palate
- Congenital heart defects
- Abnormalities of the hands and feet
- Abnormalities of the eyes, ears, and/or nose
- Abnormalities of the genitalia
- Abnormalities of the urinary tract
- Abnormalities of the central nervous system
- Abnormalities of the gastrointestinal tract
- Abnormalities of the skeletal system
- Abnormalities of the immune system
- Abnormalities of the endocrine system
- Abnormalities of the reproductive system
- Abnormalities of the skin

Methimazole embryofetopathy is a rare condition caused by the use of the antithyroid drug methimazole during pregnancy. It is thought to be caused by the drug crossing the placenta and interfering with the normal development of the fetus. It can cause a range of birth defects, including heart defects, cleft lip and palate, and limb malformations.

The primary treatment for Methimazole embryofetopathy is to discontinue the use of the drug. If the drug cannot be discontinued, then the dose should be reduced as much as possible. Other treatments may include the use of steroids, anticonvulsants, and other medications to help manage symptoms. In some cases, surgery may be necessary to correct any physical abnormalities caused by the condition.

The risk factors for Methimazole embryofetopathy include:

1. High doses of Methimazole during the first trimester of pregnancy.

2. Long-term use of Methimazole prior to pregnancy.

3. Use of Methimazole in combination with other medications.

4. Genetic predisposition.

5. Maternal age.

6. Maternal smoking.

7. Maternal alcohol consumption.

8. Maternal obesity.

At this time, there is no known cure for Methimazole embryofetopathy. However, there are medications that can be used to manage the symptoms associated with the condition. These medications include anticonvulsants, anti-inflammatory drugs, and hormone replacement therapy. Additionally, supportive care such as physical therapy, occupational therapy, and speech therapy may be beneficial.